$39.87
1.42% today
NYSE, Feb 05, 04:19 pm CET
ISIN
VGG111961055
Symbol
BHVN
Sector
Industry

Biohaven Pharmaceutical Holding Company Ltd. Stock price

$39.31
+0.44 1.13% 1M
+5.08 14.84% 6M
+1.96 5.25% YTD
-7.85 16.65% 1Y
-91.85 70.03% 3Y
-13.13 25.04% 5Y
+21.81 124.63% 10Y
NYSE, Closing price Tue, Feb 04 2025
+1.60 4.24%
ISIN
VGG111961055
Symbol
BHVN
Sector
Industry

Key metrics

Market capitalization $3.98b
Enterprise Value $3.62b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 11.81
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-848.89m
Free Cash Flow (TTM) Free Cash Flow $-531.06m
Cash position $379.40m
EPS (TTM) EPS $-9.35
P/E forward negative
Short interest 11.04%
Show more

Is Biohaven Pharmaceutical Holding Company Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Biohaven Pharmaceutical Holding Company Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Biohaven Pharmaceutical Holding Company Ltd. forecast:

13x Buy
100%

Analyst Opinions

13 Analysts have issued a Biohaven Pharmaceutical Holding Company Ltd. forecast:

Buy
100%

Financial data from Biohaven Pharmaceutical Holding Company Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 3.87 3.87
40% 40%
-
-3.87 -3.87
40% 40%
-
- Selling and Administrative Expenses 78 78
32% 32%
-
- Research and Development Expense 763 763
103% 103%
-
-845 -845
71% 71%
-
- Depreciation and Amortization 3.87 3.87
40% 40%
-
EBIT (Operating Income) EBIT -849 -849
71% 71%
-
Net Profit -804 -804
73% 73%
-

In millions USD.

Don't miss a Thing! We will send you all news about Biohaven Pharmaceutical Holding Company Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biohaven Pharmaceutical Holding Company Ltd. Stock News

Neutral
PRNewsWire
23 days ago
Presents progress and new anticipated milestones across portfolio of more than 10 assets and 6 therapeutic areas. Announces multiple advancements across the MoDETM (molecular degraders of extracellular proteins) platform and the next generation TRAPTM (targeted removal of aberrant protein) degraders, including: IgA Nephropathy (IgAN) program: First-in-human dosing with BHV-1400, a next generati...
Neutral
PRNewsWire
29 days ago
NEW HAVEN, Conn. , Jan. 7, 2025 /PRNewswire/ -- Biohaven Ltd.
Neutral
PRNewsWire
about 2 months ago
BHV-1300 achieved deep lowering of targeted IgG, with reductions > 60% in the lowest subcutaneous dose tested in the MAD. Subcutaneous BHV-1300 achieved rapid and progressive lowering of IgG within hours of each weekly dose administration, and pharmacodynamic effects were sustained relative to baseline over the four-week period.
More Biohaven Pharmaceutical Holding Company Ltd. News

Company Profile

Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.

Head office Virgin Islands, British
CEO Vladimir Coric
Employees 239
Founded 2022
Website www.biohaven.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today